About InMed
InMed is a Healthcare company based in San Diego (United States) founded in 2018 by Al Curran and Latha Poonamallee. InMed has raised $9.88 million across 7 funding rounds from investors including Exxora Trading, BIRAC and Venture Center. Its chief executive, as recorded, is Latha Poonamallee. Its Indian entity Prognostics In-Med Private Limited reported revenue of ₹3.97 Cr. Its focus areas include HealthTech, Healthcare IT, Provider and Clinical Operations. Its competitors include Viz.ai, Subtle Medical and Invicro; 3 of its 3 listed competitors have raised funding.
Company details
Provider of AI powered medical imaging and radiology solutions. It offers FDA cleared tools for brain volumetry, workflow prioritization in trauma cases, muscle and fat quantification, and lesion detection and quantification in oncology. The tools utilize research and human centered design principles. It also develops ethnicity based reference ranges for enhanced diagnostic accuracy. Its solutions provide contextually relevant reports and actionable insights for enhanced prognostics and diagnostics. Various integration and customization options are available for deployment.
- Headquarters San Diego, United States
- Founders Al Curran, Latha Poonamallee
- SectorsHealthcare
- Website inmed.ai
- Social LinkedIn
- Legal Name Prognostics In-Med Private Limited
- Date of Incorporation 10 Jan, 2018
- Jurisdiction Pune, Maharashtra, India
- Indian entity revenue₹3.97 Cr
FY 2024 · -53% YoY
- Indian entity net loss-₹14.8 Lakh
FY 2024 · -4% margin
- Indian entity EBITDA-₹6.4 Lakh
FY 2024 · -2% margin
- Total Equity Funding$9.88M (USD)
in 7 rounds
- Latest Funding Round$2.13M (USD), Seed
Dec 2022
- InvestorsExxora Trading
& 4 more
Associated legal entities of InMed
InMed operates through Prognostics In-Med Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2024) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Prognostics In-Med Private Limited CIN U72900PN2018PTC174234 | Active | 10 Jan 2018 | Pune, Maharashtra | ₹4.0 Cr | 3 | View details |
Funding Insights of InMed
InMed has successfully raised a total of $9.88M across 7 strategic funding rounds. The most recent funding activity was a Seed round of $2.13 million completed in December 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $9.88M
- Total Rounds 7
- Last Round Seed — $2.13M
- Investors Count 5
All 7 funding rounds of InMed with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2022 | $2.13M | Seed | – | Exxora Trading | – |
| Sep 2020 | $210,681 | Seed | – | – | – |
| Mar 2019 | $27,769 | Angel Round | – | – | – |
| Jan 2019 | $71,461 | Grant | – | – | |
| Jul 2018 | $7.5M | Seed | – | – | |
| Apr 2018 | $15,400 | Angel Round | – | – | – |
| Feb 2018 | Seed | – | – |
5 investors in total: 5 institutional.
Investors in InMed
InMed has secured backing from 5 investors, including venture fund investors. Prominent investors backing the company include Exxora Trading, BIRAC and Venture Center.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity firm focused on multiple sectors | exxora.tcc.mode | Panaji, India | ||
Business incubation services are provided across multiple sectors. | birac.nic.in | Delhi, India | ||
Startups are incubated at Venture Center, backed by CSIR. | venturecenter.co.in | Pune, India | ||
Venture capital firm investing in early stage startups | shasta.vc | Portola Valley, United States | ||
Investments in entertainment and technology are made by AET Fund. | aet.fund | Shinagawa, Japan |
Investor details for InMed
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Prognostics In-Med Private Limited (InMed)
Prognostics In-Med Private Limited is the primary company behind InMed. The board of Prognostics In-Med Private Limited currently have 3 directors; the longest-serving is Latha Chandrasekaran Poonamallee, appointed in 2018. 1 earlier director has ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Latha Chandrasekaran Poonamallee DIN 07867885 | Director | 10 Jan 2018 | 8 yrs 9 mo | Prognostics In-Med Private Limited |
| Rajesh Kumar Purushottam DIN 02349139 | Director | 10 Jan 2018 | 8 yrs 9 mo | Prognostics In-Med Private Limited |
| Mukund Raghunath DIN 08404211 | Director | 11 Jan 2020 | 6 yrs 9 mo | Prognostics In-Med Private Limited |
People of InMed
10 people are tracked at InMed (3 in leadership, 6 in board & advisors, 1 in team).
| Name | Role | Group |
|---|---|---|
Al Curran | Co-Founder | Leadership |
| Co-Founder & CEO | Leadership | |
Jignesh Agrawal | CFO | Leadership |
Deepak Agarwal | Scientific Advisory Board Member | Board & advisors |
Sweta Adatia | Scientific Advisory Board Member | Board & advisors |
S P Gorthi | Scientific Advisory Board Member | Board & advisors |
Rahul Kulkarni | Scientific Advisory Board Member | Board & advisors |
Anirudha Joshi | Scientific Advisory Board Member | Board & advisors |
Ramzy Ross | Scientific Advisory Board Member | Board & advisors |
Hussain Ghadiyali | Innovation Specialist | Team |
Complete people profiles for InMed
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of InMed
Figures of Prognostics In-Med Private Limited, the primary company behind InMed, for FY 2024. Revenue was ₹3.97 Cr (-53% year on year). Net loss was -₹14.8 Lakh (-4% margin). EBITDA was -₹6.4 Lakh (-2% margin). Revenue has grown at a compounded annual rate of +80% over three years and +218% over five years.
- ₹3.97 CrRevenue · FY 2024 · -53% YoY
- -₹14.8 LakhNet loss · -4% margin
- -₹6.4 LakhEBITDA · -2% margin
- ₹14.6 LakhPaid-up capital
- +80%Revenue CAGR, 3 years
- +218%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Prognostics In-Med Private Limited are on its company page.
Detailed financial statements for InMed
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of InMed
3 dated milestones of InMed across 4 years, from founding to its latest funding, stage changes and deals.
- Founded InMed is founded.
- Funding First funding round.
- Funding Latest funding round, Seed, of $2.1M.
Competitors of InMed
InMed has 3 listed competitors in our database, 3 of them funded. They include Viz.ai, Subtle Medical and Invicro.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| viz.ai | 2016 | San Francisco, United States | $251.99M | 206 | AI and cloud-powered software for stroke care coordination is developed. | |
| subtlemedical.com | 2017 | Palo Alto, United States | $18.3M | 23 | AI-driven solutions for medical diagnostic imaging are developed. | |
| invicro.com | 2008 | Boston, United States | $45.84M | 308 | Provide contract research imaging services and software |
Detailed competitors of InMed
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Clinical IT & Data Platforms
3 companies that operate in the same segment as InMed (Clinical IT & Data Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Employee health benefits are facilitated via a cloud-based platform. | 2007 | Plymouth Meeting, Pennsylvania, United States | USD 228.3 M | |||
Healthcare appointments are booked online via Zocdoc's platform. | 2007 | New York, New York, United States | USD 425.97 M | USD 4.66 M | 1,365 | |
Virtual physical therapy and digital pain care solutions are provided. | 2015 | San Francisco, California, United States | USD 854.44 M | 1,746 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Inmed
Complete news archive for InMed
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about InMed
InMed was founded in 2018.
InMed is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Latha Poonamallee is the CEO of InMed, as recorded in our data. They have also founded this company.
InMed is a funded company, having raised a total of $9.88M across 7 funding rounds to date.
The primary company behind InMed, Prognostics In-Med Private Limited, reported revenue of ₹3.97 Cr for FY 2024, down 53% year on year.
Provider of AI powered medical imaging and radiology solutions. It offers FDA cleared tools for brain volumetry, workflow prioritization in trauma cases, muscle and fat quantification, and lesion detection and quantification in oncology. The tools utilize research and human centered design principles. It also develops ethnicity based reference ranges for enhanced diagnostic accuracy. Its solutions provide contextually relevant reports and actionable insights for enhanced prognostics and diagnostics. Various integration and customization options are available for deployment.
InMed's top competitors include Subtle Medical, Viz.ai and Invicro.
InMed has 5 investors. Key investors include Exxora Trading, BIRAC, Venture Center, Shasta Ventures, and AET Fund.
InMed operates through Prognostics In-Med Private Limited.
The legal entities of InMed currently have 3 directors, including Mukund Raghunath, Latha Chandrasekaran Poonamallee, Rajesh Kumar Purushottam.